GI billing turns on a single high-stakes distinction: screening versus diagnostic colonoscopy. Add polyp-removal modifier rules, endoscopy NCCI bundling, biologic infusion capture, and surveillance medical necessity — and general billers are quickly out of their depth. MedFactor delivers gastroenterology-specific billing that protects every case.
From ambulatory endoscopy centers to hospital-based hepatology and IBD infusion programs, we tailor billing to the coding rules of every gastroenterology subspecialty.
Screening & diagnostic colonoscopy, EGD, polyp removal, and routine endoscopy with screening-vs-diagnostic accuracy.
Liver biopsy, fibrosis imaging, cirrhosis management, and transplant evaluation coding with NCCI-aware bundling.
Crohn's & ulcerative colitis biologic infusion billing — J-code selection, waste calculation, and administration capture.
ERCP, endoscopic ultrasound (EUS), stent placement, and complex therapeutic endoscopy coding with add-on capture.
Manometry, pH monitoring, Bravo placement, and functional GI disorder testing with proper technical/professional splits.
Capsule endoscopy (91110), Bravo pH, and reflux monitoring with medical-necessity documentation and prior auth.
Miscoding this single distinction is the largest source of lost GI revenue and patient cost-share disputes. Get it right and every colonoscopy is paid correctly.
Asymptomatic, average- or high-risk screening performed at surveillance intervals — no cost-share under the ACA when coded correctly.
Performed for symptoms, abnormal findings, surveillance of prior disease, or with intervention (biopsy, polypectomy) — billed to the diagnostic code set with applicable modifiers.
GI billing is governed by screening rules, endoscopy bundling, and infusion coding that general billing companies cannot navigate effectively.
Miscoding a screening colonoscopy as diagnostic (or vice versa) triggers patient cost-share disputes, payer denials, and lost preventive-benefit coverage.
Multiple polypectomies (45380/45385) in one session trigger MPPR. Missing modifier 59 for distinct sites leaves add-on revenue unbilled.
Diagnostic endoscopy is bundled into therapeutic endoscopy at the same session. Billing components separately causes NCCI denials and compliance risk.
Infliximab and other IBD biologics require J-code selection, waste calculation, and administration codes (96365) — frequently under-billed or missing.
Repeat colonoscopy before the surveillance interval is denied without documented medical necessity — a common cause of high-dollar endoscopy denials.
Anesthesia for endoscopy is billed separately from the procedure. Mismanaged anesthesia billing loses facility and professional revenue per case.
Quick reference for the most frequently used codes in gastroenterology billing and coding.
| Code | Description | Common Use |
|---|---|---|
| 45378 | Colonoscopy, flexible, diagnostic | Base diagnostic colonoscopy |
| 45380 | Colonoscopy with biopsy | Single/multiple biopsy |
| 45385 | Colonoscopy with snare polypectomy | Polyp removal |
| 43239 | EGD with biopsy | Upper endoscopy + biopsy |
| 43259 | ERCP, diagnostic | Biliary/pancreatic endoscopy |
| 91110 | Capsule endoscopy | Small-bowel capsule imaging |
| 96365 | IV infusion, therapeutic, first hour | Biologic infusion administration |
| G0121 | Colorectal screening colonoscopy, not high risk | Average-risk screening |
| G0105 | Colorectal screening colonoscopy, high risk | High-risk screening |
| 43200 | EGD, diagnostic | Upper endoscopy, diagnostic |
| Code | Description | Clinical Context |
|---|---|---|
| K57.x | Diverticular disease | Diverticulitis / surveillance |
| K50.x | Crohn's disease | IBD — biologic indication |
| K51.x | Ulcerative colitis | IBD — biologic indication |
| K92.x | GI hemorrhage | Diagnostic colonoscopy / EGD |
| K21.x | Gastro-esophageal reflux disease | EGD / surveillance |
| K59.x | Functional / constipation | Diagnostic workup |
| K70.x | Alcoholic liver disease | Hepatology management |
| K74.x | Cirrhosis / fibrosis | Liver biopsy / transplant eval |
| C18-20 | Colorectal malignancy | Surveillance / therapeutic |
| K76.x | Other liver disease | Hepatology / imaging |
| Modifier | Description | GI Application |
|---|---|---|
| 33 | Preventive services | Screening colonoscopy on commercial/PPO plans |
| PT | Screening converted to diagnostic | Colonoscopy started as screening, became diagnostic |
| 59 | Distinct procedural service | Multiple polyps at distinct sites same session |
| 51 | Multiple procedures | Multiple endoscopic procedures same session |
| 25 | Separate E/M service | Significant E/M same day as endoscopy |
| 52 | Reduced services | Incomplete colonoscopy to cecum |
| 22 | Increased procedural service | Unusually complex endoscopy |
| 26 / TC | Professional / technical component | Motility, pH monitoring, imaging interpretation |
Comprehensive revenue cycle management designed specifically for gastroenterology practices and endoscopy centers.
Specialty-trained coders handle screening/diagnostic colonoscopy, EGD, ERCP, and infusion coding with modifier accuracy.
Proactive screening-rule defense, NCCI bundling compliance, and appeals with procedural documentation for GI denials.
Pre-procedure authorization for biologics, ERCP, advanced imaging, and capsule endoscopy with medical-necessity support.
Prioritized follow-up on aged endoscopy and infusion claims with strategic payer escalation to maximize recovery.
Regular audits focused on screening/diagnostic accuracy, modifier 33/PT/59, NCCI bundling, and surveillance medical necessity.
Real-time dashboards tracking screening accuracy, infusion volume, procedure-level profitability, and physician productivity.
Understanding the most common denial reasons is the first step to preventing them on endoscopy and infusion claims.
Screening colonoscopy billed as diagnostic (or reverse) without modifier 33/PT or the correct G-code.
Pre-procedure indication review to assign the correct screening vs diagnostic code and modifier before submission.
Multiple polypectomies (45380/45385) at distinct sites billed without modifier 59, losing add-on revenue.
Site-specific modifier 59 for distinct polyp locations and full add-on capture for every therapeutic intervention.
Diagnostic endoscopy billed separately from same-session therapeutic endoscopy, triggering NCCI edits.
NCCI-aware coding that bundles diagnostic into therapeutic correctly, preserving legitimately distinct procedures.
J-code selection errors, missing waste calculation, or administration codes (96365) not billed for IBD biologics.
Accurate J-code selection with waste documentation and full administration-code capture for every infusion.
Identifying and plugging these common revenue leakage points can significantly improve your bottom line.
Screening colonoscopy converted to diagnostic billed without modifier PT, losing correct diagnostic reimbursement.
Biopsy/polypectomy add-ons (45380/45385) not billed when a diagnostic colonoscopy includes intervention.
Biologic administration codes (96365) and J-code waste missed on IBD infusion visits, losing $120–400 per infusion.
Repeat colonoscopy before surveillance interval denied because medical necessity wasn't documented pre-procedure.
See how gastroenterology-specific revenue cycle management transforms your practice's financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
Review of GI billing operations, screening/diagnostic accuracy, denial patterns, and revenue cycle baseline.
EMR/endoscopy-system integration, dedicated GI billing team, workflow configuration, and payer enrollment verification.
Full billing operations with real-time claim submission, biologic authorization, and denial prevention protocols.
Performance review against baseline, workflow optimization, and documented improvement in denials, A/R, and screening accuracy.
How our GI-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor GI |
|---|---|---|---|
| Screening vs diagnostic colonoscopy accuracy | Inconsistent | ✕ | ✓ |
| Modifier 33 / PT / 59 expertise | ✕ | ✕ | ✓ |
| Polyp add-on (45380/45385) capture | Inconsistent | ✕ | ✓ |
| Endoscopy NCCI bundling compliance | ✕ | ✕ | ✓ |
| Biologic infusion J-code & admin billing | Manual | ✕ | ✓ |
| Surveillance medical-necessity documentation | ✕ | Partial | ✓ |
| Biologic & ERCP prior authorization | Manual | Partial | ✓ |
| Screening-accuracy reporting | ✕ | ✕ | ✓ |
| Infusion-volume & profitability analytics | ✕ | ✕ | ✓ |
| Dedicated GI billing team | ✕ | ✕ | ✓ |
Our team combines deep gastroenterology billing expertise with the technology and processes to deliver consistent, measurable results for practices and endoscopy centers of every size.
Discover exactly where your gastroenterology practice is losing revenue. Our no-obligation audit analyzes your screening accuracy, modifier compliance, and infusion capture.
Real results from gastroenterology practices that partnered with MedFactor for specialty revenue cycle management.
An ambulatory endoscopy center was miscoding screening colonoscopy as diagnostic and dropping modifier PT on conversions. MedFactor implemented pre-procedure indication review, recovering substantial undercharged revenue in six months.
A high-volume IBD infusion clinic was under-billing biologic administration and J-code waste. MedFactor implemented systematic infusion capture, recovering revenue that had been silently lost per infusion.
An advanced endoscopy practice was losing add-on revenue on therapeutic colonoscopy and ERCP. MedFactor implemented modifier 59 and add-on capture protocols that protected multi-procedure revenue.
No matter where your gastroenterology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Common questions from GI practices considering MedFactor's specialty RCM services.
A screening colonoscopy is performed on an asymptomatic patient at average or high risk per surveillance intervals, while a diagnostic colonoscopy is performed for symptoms, abnormal findings, or surveillance of known disease. Screening uses HCPCS G0121 (average risk) or G0105 (high risk) for Medicare, or CPT 45378 with modifier 33 for commercial plans. Diagnostic uses 45378 as the base with therapeutic add-ons (45380 biopsy, 45385 polypectomy). We confirm the indication pre-procedure so the correct code set is assigned — protecting the ACA no-cost-share screening benefit and preventing diagnostic denials.
Modifier PT is appended when a colonoscopy that began as a screening is converted to a diagnostic or therapeutic procedure — for example, when a polyp is found and removed during a screening exam. This tells the payer the case started as screening (preserving the screening benefit) but became diagnostic. Without modifier PT, the claim is denied or the patient loses the no-cost-share protection. We apply PT on every screening-to-diagnostic conversion and pair it with the correct therapeutic add-on codes.
When multiple polyps are removed during one colonoscopy, the therapeutic codes (45380 for biopsy, 45384 for hot biopsy, 45385 for snare polypectomy) capture the highest-intensity intervention, and additional distinct methods or sites may be billed with modifier 59 (distinct procedural service) when supported by documentation. CMS MPPR reduces payment on additional procedures. We document each polyp's location and removal method, sequence the highest-value code first, and apply modifier 59 only where anatomically distinct — maximizing legitimate add-on capture without triggering NCCI denials.
IBD biologic infusions (infliximab and others) require the drug J-code billed per dosing unit, the administration code 96365 (therapeutic IV infusion, first hour) with add-on hours, and accurate waste calculation when a vial isn't fully used. We verify the biologic's J-code and dosing per patient weight, document wasted drug with the JW modifier where applicable, and capture every administration component — recovering revenue general billers routinely miss, often $120–400 per infusion.
NCCI procedure-to-procedure edits bundle a diagnostic endoscopy into a therapeutic endoscopy performed at the same session on the same anatomy — the diagnostic look is considered part of the therapeutic intervention and cannot be billed separately. We apply these edits before submission so the diagnostic component is correctly bundled, while preserving legitimately separate procedures (different anatomy or distinct encounters) with modifier 59 where appropriate. This prevents denials and the compliance risk of double-billing bundled components.
We integrate with all major GI EMR and endoscopy reporting platforms including Epic, Cerner, Athenahealth, gGastro, Modernizing Medicine, and ProVation, plus infusion-center and practice management systems. Our team works with your endoscopy reporting and infusion workflows so procedure documentation, polyp findings, and infusion data flow cleanly to correct claim submission — including the screening indication and modifier details that drive accurate colonoscopy coding.
MedFactor applies the same code-level precision across the full practice spectrum. See how we bill these related specialties.
CPT®, ICD-10, HCPCS, and modifier codes referenced on this page reflect the current code sets and are subject to annual updates — always verify against the current-year fee schedule before submission. KPIs and case-study figures shown are representative benchmarks, not guarantees of individual practice results.
Your GI practice deserves billing partners who know the difference between screening G0121 and diagnostic 45378 — and code every conversion with modifier PT. Let MedFactor show you what specialty RCM can do.